On October 6, 2021 MPM Capital ("MPM"), one of the world’s leading biotech investment firms, reported that it has raised $850 million for its second Oncology Impact Fund ("OIF 2" or "the Fund"), making it the world’s largest biotech impact investment fund (Press release, MPM Capital, OCT 6, 2021, View Source [SID1234590880]). OIF 2’s investment efforts are managed through BioImpact Capital, an affiliate of MPM that has been formed to broaden MPM’s investment offerings beyond venture capital into dedicated impact and public equities funds.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OIF 2 will create and invest in companies that develop innovative treatments for cancer and other areas of highest unmet medical need. The Fund’s goals are to generate a compelling financial return and a long-term impact on patients’ lives. OIF 2 will invest in private and public companies to identify the most compelling drug development programs.

OIF 2 exceeded its fundraising target of $650 million, and far outpaced the $471 million raised in 2016 for MPM’s first Oncology Impact Fund ("OIF 1"), which at the time was also the largest biotech impact investment fund ever.

MPM and its BioImpact Capital team raised $650 million for OIF 2 through their unique partnership with UBS, the world’s leading global wealth manager. UBS clients invested from around the world including the US, the UK, Switzerland, Hong Kong, and Singapore. The remaining $200 million was raised by MPM and the BioImpact Capital team directly.

"Beyond oncology, OIF 2 will also expand its focus to additional cutting-edge technologies including cell, gene, and RNA therapies," said Ansbert Gadicke, M.D., Managing Partner of BioImpact Capital and MPM Managing Director. "Companies created by MPM remain at the vanguard of innovation, having received FDA approvals for over 50 drugs. Their continued success now stands to benefit an even greater range of investors and patients."

MPM and its BioImpact Capital team are equally committed to generating significant social and human impact through OIF 2 and doing so without affecting investor returns. A portion of its success fees from OIF 2, as well as a royalty from treatments created by its start-up companies, will be donated to the American Association for Cancer Research (AACR) (Free AACR Whitepaper), to help fund grants for next-generation cancer research, and to the UBS Optimus Foundation, to improve access to cancer care in the developing world.

"Through OIF 2, our mission is twofold: providing strong financial returns for our investors, while creating broader impact for patients even beyond the life-saving drugs we create," said Christiana Bardon, M.D., M.B.A., Co-Managing Partner of BioImpact Capital. "The companies that we invest in are all motivated to transform the lives of patients. Our novel investment model in partnership with philanthropic organizations can amplify the benefit to patients by supporting expanded patient access and the next generation of scientific insights."

"We are proud to connect our clients with brilliant scientists around the world who are working hard to alleviate the pain and suffering caused by cancer," said Mark Haefele, Chief Investment Officer at UBS Global Wealth Management. "With more than $1 billion raised so far, this is what reimagining the power of investing and connecting people for a better world can look like."

MPM’s BioImpact Capital team leverages its extensive company creation and clinical development experience along with its deep research and intellectual property expertise to successfully create and invest in companies through clinical proof of concept. In total, MPM has shepherded more than 100 companies through

On October 6, 2021 PanTher Therapeutics (PanTher), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, reported the dosing of the first two patients in its Phase 1 first-in-human clinical trial of PTM-101 for the treatment of pancreatic cancer (Press release, PanTher Therapeutics, OCT 6, 2021, View Source [SID1234590879]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PanTher’s proprietary treatment platform focuses on direct, localized, and sustained delivery of proven and novel therapeutic agents, attacking cancer at the source. Pancreatic cancer has one of the poorest prognoses of all malignancies, and responses to currently available systemic therapies are inadequate. PTM-101 is PanTher’s lead clinical candidate and is designed to intensively target pancreatic tumors and enhance therapeutic effect with minimal systemic toxicity.

This first-in-human trial will evaluate feasibility, safety, and pharmacokinetics of PTM-101 when used as part of a standard procedure for treatment of patients with locally advanced pancreatic adenocarcinoma.

"Launching the PTM-101 Phase 1 trial signals a major step toward our goal of improving therapeutic options for patients with difficult-to-treat solid tumors," said Laura Indolfi, PhD, Chief Executive Officer of PanTher Therapeutics. "We are thrilled to partner with Dr. Charles Pilgrim and his team at The Alfred Hospital in Melbourne as we incorporate PTM-101 into the treatment for patients with locally advanced pancreatic cancer."

The principal investigator of the PTM-101 clinical trial is Charles Pilgrim, MBBS, FRACS, PhD, FACS, who is an Associate Professor of Surgery at The Alfred, Central Clinical School, Monash University and a Senior trauma instructor and examiner for the Royal Australasian College of Surgeons. Dr. Pilgrim is a surgeon-scientist with a clinical and research focus on pancreas and hepatobiliary cancers, a PhD through the University of Melbourne at Peter MacCallum Cancer Centre, and a second fellowship in Surgical Oncology/HPB surgery at the Medical College of Wisconsin.

"Based upon the encouraging data in animal models of pancreatic cancer, we are optimistic about the clinical potential of PTM-101 to treat patients with this devastating disease," said J. Marc Pipas, MD, Chief Medical Officer of PanTher Therapeutics. "Our hope is that this technology will provide physicians a novel therapeutic modality without disrupting the current standard of care. The initiation of this first-in-human study could represent an important advance in the treatment of pancreatic cancer."

About PTM-101

PanTher’s lead clinical candidate, PTM-101, is a proprietary flexible biodegradable polymeric system for the sustained release of paclitaxel to the tumor site. It allows easy integration with standard procedures to specifically target the peritumoral area.

On October 6, 2021 SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors, reported that it will host a virtual R&D Day on Wednesday, October 13, 2021, at 10:00 a.m. ET to showcase its versatile DiversitAb platform and pipeline of clinical and preclinical programs (Press release, SAB Biotherapeutics, OCT 6, 2021, View Source [SID1234590878]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will feature SAB management and key opinion leaders, including:

Arturo Casadevall, MD, PhD – The Alfred and Jill Sommer Professor and Chair, W. Harry Feinstone Department of Molecular Microbiology & Immunology, Bloomberg Distinguished Professor, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins School of Medicine
Michael Haller, MD, MS-CI – Professor and Chief, Silverstein Family Eminent Scholar, Pediatric Endocrinology in the College of Medicine, University of Florida
A live webcast of the event will be accessible through the "News" section of the company’s website at www.sabbiotherapeutics.com. A replay of the webcast will be available on the SAB website following the event.

On June 22, 2021, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP). The transaction is expected to close in the fourth quarter of 2021.

On October 6, 2021 NextEra Energy, Inc. (NYSE: NEE) reported that it plans to report third-quarter 2021 financial results before the opening of the New York Stock Exchange on Wednesday, Oct. 20, 2021, in a news release to be posted on the company’s website at www.NextEraEnergy.com/FinancialResults (Press release, Nextera, OCT 6, 2021, View Source [SID1234590875]). The company will issue an advisory news release over PR Newswire the morning of Oct. 20, with a link to the financial results news release on the company’s website. As previously communicated, the company will make available its financial results only on its website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jim Robo, chairman and chief executive officer of NextEra Energy, Rebecca Kujawa, executive vice president, finance and chief financial officer of NextEra Energy, and other members of the company’s senior management team will discuss the company’s third-quarter 2021 financial results during an investor presentation to be webcast live, beginning at 9 a.m. ET on Oct. 20. Results for NextEra Energy Partners, LP (NYSE: NEP) also will be discussed during the same investor presentation.

The listen-only webcast will be available on NextEra Energy’s website by accessing the following link: www.NextEraEnergy.com/FinancialResults. The financial results news release and the slides accompanying the presentation may be downloaded at www.NextEraEnergy.com/FinancialResults, beginning at 7:30 a.m. ET on the day of the webcast. A replay will be available for 90 days by accessing the same link as listed above.

On October 6, 2021 OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, reported that it will present three abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting being held in Washington D.C. and virtually November 10-14, 2021 (Press release, OncoResponse, OCT 6, 2021, View Source [SID1234590874]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to be highlighting several preclinical findings at the SITC (Free SITC Whitepaper) conference demonstrating the application of our propriety immunotherapy platform we are utilizing to discover and develop therapeutic antibodies that modulate the tumor microenvironment. This includes preclinical findings for our lead therapeutic candidate, OR2805, which has entered clinical development," said Clifford Stocks, Chief Executive Officer of OncoResponse.

Details of the poster presentations are as follows:

Title: Development of OR2805, an anti-CD163 antibody derived from an elite responder to checkpoint inhibitor therapy that relieves immunosuppression caused by M2c macrophages

Poster/Abstract Number: 271
Date/Time: Friday, November 12, 7:00 a.m. to 8:30 p.m. ET

Title: Preclinical characterization of humanized anti-Siglec-15 antibodies that rescue T cells from macrophage-mediated immune suppression

Poster/Abstract Number: 262
Date/Time: Saturday, November 13, 2021, 7:00 a.m. – 8:30 p.m. EST

Title: Discovery and preclinical characterization of anti-LILRB2 antibodies that rescue T cells from macrophage-mediated immune suppression

Poster/Abstract Number: 276
Date/Time: Saturday, November 13, 2021, 7:00 a.m. – 8:30 p.m. EST

Poster presentations will be accessible in person and virtually. Onsite posters will be displayed in the SITC (Free SITC Whitepaper) Poster Hall located in Hall E of the convention center. ePosters will be available for SITC (Free SITC Whitepaper) attendees on Nov. 12 at 7 am ET and can be accessed on the SITC (Free SITC Whitepaper) virtual meeting site.

About OR2805

OR2805 is a fully human antibody discovered using B cells derived from an elite responder to checkpoint inhibitor (CPI) therapy. This antibody binds to CD163 which is highly expressed on tumor associated macrophages (TAMs) that create an immunosuppressive tumor microenvironment and inhibit anti-tumor T-cell responses. High frequency of CD163-expressing TAMs generally predicts an unfavorable prognosis in solid tumors. OR2805 is designed to improve anti-tumor T-cell responses, by reversing the immunosuppression of TAMs, as a therapeutic strategy for monotherapy and in combination with CPI.